The U.S. Food and Drug Administration on September 16 handed Neptune Medical a 510(k) clearance for its Triton 1 Robotic Endoscopy System, opening the door to the first commercial deployment of the Burlingame, California company's Dynamic Rigidization technology in a fully robotic colonoscopy platform.
What Dynamic Rigidization Actually Does
Standard flexible endoscopes lose control the moment they meet a loop of colon, forcing physicians to reposition patients, apply manual pressure or convert cases. Neptune's Dynamic Rigidization overtube stiffens the shaft on demand, letting Triton drive itself through the entire colon while the endoscopist works the controls. In the CARE 1 pivotal trial the system logged a 100% cecal intubation rate, no adverse events and — measured against the industry's 35% benchmark — a 54.2% adenoma detection rate, the metric most closely tied to colorectal cancer prevention.
The same trial recorded a 67% lower average clinician burden versus manual colonoscopy on the NASA-TLX workload scale, with no patient repositioning or manual conversion required across the enrolled cohort.
Where Triton Fits In A Crowded Surgical-Robotics Field
Triton lands into a robotic-endoscopy market that has been slower to consolidate than laparoscopic surgery, in part because colon procedures reward reach and adenoma detection over the wristed dexterity a da Vinci-style platform delivers. Neptune's Pathfinder overtube is already in clinical use as a manual accessory; Triton adds motorised advancement and a robotic control interface, positioning the company alongside recent robotic-endoscopy entrants such as Medtronic's Hugo platform, which just cleared robotic LigaSure Maryland on the same day.
Commercial Rollout And What Comes Next
CEO Alex Tilson said Triton "has the potential to fundamentally transform colonoscopy, creating a better experience for both physicians and their patients." UC Irvine's Jason B. Samarasena, a CARE 1 investigator, framed the clearance as "the possibility of one system that can screen and treat anywhere in the colon, efficiently, thoroughly."
Neptune has not disclosed pricing or a national rollout schedule, but the 510(k) clears the path for controlled hospital placements starting later this year. Reimbursement will lean on existing colonoscopy CPT codes plus any incremental hospital-side upcharge for robotic capital equipment, similar to the reimbursement pattern for Spineart's PERLA TL and other recent robotic clearances.
Reporting based on Neptune Medical's press release via BioSpace and Business Wire (September 16, 2026).